Gritstone bio, Inc. Common Stock

GRTS

Börsenwert 3,8 Mio. $

EMERYVILLE, Calif.--(BUSINESS WIRE)--Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternati.

On Monday, Gritstone Bio Inc. GRTS revealed interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline microsatellite-stable colorectal cancer (MSS-CRC).

--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.31 per share a year ago.

-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer --

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Gritstone bio, Inc. (NASDAQ: GRTS) on behalf of long-term stockholders following a class action complaint that was filed against Gritstone on June 7, 2024 with a Class Period from March 9, 2023 to February 29, 2024. Our investigation concerns whether the board of directors of Gritstone have breached their fiduciary duties to the company.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ: GRTS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=94180&wire=1 or contact Joseph E. Levi, Esq.

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ: GRTS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.